Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8734446 | Pediatric Hematology Oncology Journal | 2016 | 6 Pages |
Abstract
Vincristine is one of the commonest chemotherapeutic agents in the practice of pediatric oncology. Although peripheral neuropathy is a dose limiting adverse event, blindness secondary to vincristine is seldom reported. We describe a child with Wilms tumor who developed transient visual loss after administration of vincristine. The child underwent early surgery and vincristine was re-introduced at reduced doses and gradually escalated to full dose while closely monitoring for recurrence. Blindness is a distressing adverse event, and re-exposure to the offending agent involves a conscientious decision.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Sidharth Totadri, Amita Trehan,